© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
June 01, 2022
Expert cardiologists share strategies for educating patients on the treatment and management of hypertrophic cardiomyopathy.
Drs Steve R. Ommen, Martin S. Maron, Javed Butler, and James Januzzi provide insight on the evolving treatment landscape for obstructive hypertrophic cardiomyopathy.
A panel of experts in cardiovascular medicine review the use of mavacamten as seen in the VALOR-HCM study for patients with symptomatic oHCM who are eligible for septal reduction therapy.
Martin S. Maron, MD, examines long-term data with mavacamten for oHCM treatment that was presented at ACC 2022.
David B. Glasser, MD: The Larger Implications of Telehealth in Ophthalmology
Inequities Continue to Exist in Ophthalmology Care
Postoperative Macular Hole Outcomes Benefit from Vitrectomy Without Delay